☆ 4.4 Article

Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Dermatology

Cardiovascular comorbidity in psoriasis - psoriatic inflammation is more than just skin deep

Katharina S. Kommoss et al.

Summary: This article reviews the systemic inflammation in psoriasis and its association with cardiovascular inflammation. It emphasizes the importance of managing possible comorbidities, including psychological, metabolic, and cardiovascular disease, in psoriasis patients.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2023)

添加到收藏夹

Review Dermatology

Current developments and perspectives in psoriasis

Michael P. Schoen et al.

Summary: The study of psoriasis has provided new insights into immunologic regulation and innovative therapies. This review summarizes the current research on psoriasis, focusing on pathophysiological processes and advancements in biologics and small molecule drugs. By studying psoriasis, we are gaining a better understanding of the interplay between the innate and adaptive immune systems and identifying important future research directions and therapeutic developments. The ultimate goal is to develop personalized prevention and treatment strategies.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2023)

添加到收藏夹

Article Dermatology

Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients

L. Mastorino et al.

Summary: Many European national guidelines recommend initial treatment with anti-TNF-alpha adalimumab for psoriasis and psoriatic arthritis due to economic reasons. This study evaluated the efficacy and safety of IL-17 and IL-23 inhibitors for patients who had previously received adalimumab treatment compared to adalimumab-naive patients. The findings suggested that there were no significant differences in efficacy between IL-17 and IL-23 inhibitors for both adalimumab-experienced and adalimumab-naive patients.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

添加到收藏夹

Letter Dermatology

Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis

Luca Mastorino et al.

EXPERIMENTAL DERMATOLOGY (2023)

添加到收藏夹

Article Rheumatology

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis

Iain B. McInnes et al.

Summary: In patients with active psoriatic arthritis, guselkumab provided durable improvements in multiple disease domains over a 2-year period with no unexpected safety findings.

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?

Luca Mastorino et al.

Summary: Available evidence on the management of psoriasis patients with a history of malignancies is scarce. However, treatment with biologics targeting TNFalpha, IL17, IL23, and IL12 appears to be safe in patients with previously diagnosed cancer. The use of Risankizumab and brodalumab in this special population is also reported.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study

Paolo Dapavo et al.

Summary: This study compared the efficacy, safety, and drug survival of anti TNF-alpha, anti-IL-17, and anti-IL-23 in psoriasis treatment. Ixekizumab showed superior efficacy in terms of PASI90 and PASI100, but did not have higher drug survival as expected. Secukinumab was the only drug with higher drug survival among bio-naive patients.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Therapy of psoriasis during pregnancy and breast-feeding

Galina Balakirski et al.

Summary: In the last decade, multiple systemic drugs have been approved for the treatment of psoriasis vulgaris and psoriasis arthritis (PsA). However, treatment decisions for women planning a pregnancy, as well as pregnant and lactating women, are challenging due to limited data. Topical corticosteroids have the strongest evidence for psoriasis therapy during pregnancy. Medically controlled use of UVB-therapy is also considered safe. TNF-alpha inhibitors have the best evidence for systemic therapy during pregnancy and lactation. Personalized therapeutic approaches should be based on the severity of psoriasis and patient's comorbidities.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2022)

添加到收藏夹

Article Dermatology

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry

Martina Kojanova et al.

Summary: This study evaluated the efficacy, safety, and drug survival of IL-17 inhibitors for the treatment of psoriasis. The results showed that all IL-17 inhibitors had significant improvement in the disease scores and quality of life, with good safety profiles. Brodalumab showed the highest effectiveness and drug survival probability.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study

Matteo Megna et al.

Summary: This real-life study compared the efficacy and safety of anti-IL23 drugs for psoriasis management, and found that guselkumab, tildrakizumab, and risankizumab showed comparable efficacy and safety profiles, with guselkumab and risankizumab appearing slightly more effective for palmoplantar lesions in the short term.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Letter Dermatology

Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis

G. Avallone et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

添加到收藏夹

Article Dermatology

Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study

Tiago Torres et al.

Summary: This study analyzed drug survival data of several drugs in a large international cohort, finding that IL-23 inhibitors had the highest drug survival rates, with risankizumab and guselkumab showing the best overall cumulative probabilities.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis

Zenas Z. N. Yiu et al.

Summary: The results of this cohort study suggest that guselkumab had the highest drug survival among the included biologics for treating psoriasis in terms of effectiveness, and guselkumab had the highest drug survival for safety compared with other biologics except ustekinumab.

JAMA DERMATOLOGY (2022)

添加到收藏夹

Review Dermatology

Biologics for pediatric moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis

I-Hsin Huang et al.

Summary: This study compared the efficacy and safety of biologic treatments for pediatric psoriasis approved by the FDA and EMA. The results showed that biologic treatments were effective in improving PASI scores and had a low risk of adverse events. SEC-L showed the best response in terms of PASI improvement.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)

T. Graier et al.

Summary: In this study, the effectiveness and safety of IL-23p19 inhibitors in real-world patients were analyzed. Few differences in PASI improvement were detected among biologic-naive and biologic-non-naive patients treated with different IL-23p19 inhibitors after correction for previous biologic exposure. IL-23p19 inhibitors represent a promising treatment alternative for patients who have not responded to previous biologics.

SCIENTIFIC REPORTS (2022)

添加到收藏夹

Review Dermatology

Considerations for patients with psoriasis travelling under immunosuppression

Brigitte Stephan et al.

Summary: With the establishment of modern systemic therapies for psoriasis, comprehensive consultation is required for traveling with immune modulation. Logistic aspects, climatic peculiarities, drug dependent risks, vaccinations and preventive measures must be considered. Special features of vaccinations while under immunosuppression according to current national recommendations should be taken into account.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2021)

添加到收藏夹

Article Dermatology

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Paolo Gisondi et al.

Summary: The study provides expert consensus recommendations for treat-to-target strategy in psoriasis, focusing on clinical remission, quality of life, abrogation of systemic inflammation, and safety. Treatment goals should be achieved within 3-4 months, with a 90% improvement in PASI score or a PASI score of less than or equal to 3, as well as improvements in quality of life and satisfaction.

DERMATOLOGY AND THERAPY (2021)

添加到收藏夹

Article Dermatology

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Tiago Torres et al.

Summary: In this study, drug survival analysis of the most recent biologic agents approved for the treatment of psoriasis was conducted. Factors such as female sex, higher BMI, and prior exposure to biologic agents were found to significantly increase the risk of drug discontinuation. The study also showed that the drug survival of guselkumab and risankizumab was higher than that of ustekinumab, while secukinumab had a lower drug survival rate.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan

Megumi Kishimoto et al.

JOURNAL OF DERMATOLOGY (2020)

添加到收藏夹

Article Dermatology

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial

A. Blauvelt et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

添加到收藏夹

Review Medicine, General & Internal

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review

April W. Armstrong et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Rheumatology

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52

Josef S. Smolen et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

添加到收藏夹

Review Dermatology

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis

S. K. Mahil et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Kristian Reich et al.

LANCET (2019)

添加到收藏夹

Article Medicine, General & Internal

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

Kristian Reich et al.

LANCET (2019)

添加到收藏夹

Article Dermatology

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions A Secondary Analysis of 2 Randomized Clinical Trials

Peter Foley et al.

JAMA DERMATOLOGY (2018)

添加到收藏夹

Letter Dermatology

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)

Andrew Blauvelt et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.